CA2298414A1 - Method for preventing and treating hearing loss using a neurturin protein product - Google Patents
Method for preventing and treating hearing loss using a neurturin protein product Download PDFInfo
- Publication number
- CA2298414A1 CA2298414A1 CA002298414A CA2298414A CA2298414A1 CA 2298414 A1 CA2298414 A1 CA 2298414A1 CA 002298414 A CA002298414 A CA 002298414A CA 2298414 A CA2298414 A CA 2298414A CA 2298414 A1 CA2298414 A1 CA 2298414A1
- Authority
- CA
- Canada
- Prior art keywords
- preventing
- protein product
- hearing loss
- treating hearing
- neurturin protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
Abstract
The present invention relates generally to methods for preventing and/or treating injury or degeneration of cochlear hair cells and spiral ganglion neurons by administering a neurturin neurotrophic factor protein product. The invention relates more specifically to methods for treating sensorineural hearing loss.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5418497P | 1997-07-30 | 1997-07-30 | |
US60/054,184 | 1997-07-30 | ||
US09/106,486 US6043221A (en) | 1997-07-30 | 1998-06-29 | Method for preventing and treating hearing loss using a neuturin protein product |
US09/106,486 | 1998-06-29 | ||
PCT/US1998/014600 WO1999006064A1 (en) | 1997-07-30 | 1998-07-17 | Method for preventing and treating hearing loss using a neurturin protein product |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2298414A1 true CA2298414A1 (en) | 1999-02-11 |
CA2298414C CA2298414C (en) | 2004-09-28 |
Family
ID=26732740
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002298414A Expired - Fee Related CA2298414C (en) | 1997-07-30 | 1998-07-17 | Method for preventing and treating hearing loss using a neurturin protein product |
Country Status (10)
Country | Link |
---|---|
US (2) | US6043221A (en) |
EP (1) | EP1005358B1 (en) |
JP (1) | JP2001525316A (en) |
AT (1) | ATE230607T1 (en) |
AU (1) | AU8658298A (en) |
CA (1) | CA2298414C (en) |
DE (1) | DE69810635T2 (en) |
DK (1) | DK1005358T3 (en) |
ES (1) | ES2190093T3 (en) |
WO (1) | WO1999006064A1 (en) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6043221A (en) * | 1997-07-30 | 2000-03-28 | Amgen Inc. | Method for preventing and treating hearing loss using a neuturin protein product |
DE19807426A1 (en) * | 1998-02-23 | 1999-10-14 | Otogene Biotechnologische Fors | Procedure for the treatment of diseases or disorders of the inner ear |
US6423321B2 (en) | 1999-02-24 | 2002-07-23 | Edward L. Tobinick | Cytokine antagonists for the treatment of sensorineural hearing loss |
US7053200B1 (en) | 1999-06-01 | 2006-05-30 | Baylor College Of Medicine | Compositions and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis, and abnormal cell proliferation |
WO2000073764A2 (en) | 1999-06-01 | 2000-12-07 | Baylor College Of Medicine | Composition and methods for the therapeutic use of an atonal-associated sequence |
DE10025152A1 (en) * | 2000-05-23 | 2001-12-06 | Marlies Knipper | Treatment of noise- or age-induced hearing deficiency, comprises using neurotrophin stimulating agents to counteract cochlear neurodegeneration |
US20050222070A1 (en) | 2002-05-29 | 2005-10-06 | Develogen Aktiengesellschaft Fuer Entwicklungsbiologische Forschung | Pancreas-specific proteins |
US20050171579A1 (en) * | 2001-11-09 | 2005-08-04 | Claudia Tasche | Stimulating device |
AUPR879201A0 (en) * | 2001-11-09 | 2001-12-06 | Cochlear Limited | Subthreshold stimulation of a cochlea |
US20100030130A1 (en) * | 2001-11-09 | 2010-02-04 | Cochlear Limited | Pharmaceutical intervention for modulation of neural plasticity |
US20100030301A1 (en) * | 2001-11-09 | 2010-02-04 | Cochlear Limited | Electrical stimulation for modulation of neural plasticity |
AU2003208900A1 (en) * | 2002-01-30 | 2003-09-02 | House Ear Institute | L-carnitine for treatment of hearing loss |
AU2003238178A1 (en) | 2002-05-29 | 2003-12-12 | Develogen Aktiengesellschaft Fur Entwicklungsbiologische Forschung | Pancreas-specific proteins |
CN100335502C (en) * | 2002-06-27 | 2007-09-05 | 学校法人日本医科大学 | Method of detecting perilymphatic fistula |
AU2003259846A1 (en) * | 2002-08-16 | 2004-03-03 | The General Hospital Corporation | Non-invasive functional imaging of peripheral nervous system activation in humans and animals |
US7390482B2 (en) | 2002-10-02 | 2008-06-24 | Anges Mg, Inc. | Drug for auditory dysfunction |
EP1631259A4 (en) | 2002-12-18 | 2006-08-02 | Hough Ear Inst | Otologic nanotechnology |
US8651113B2 (en) * | 2003-06-18 | 2014-02-18 | Swr&D Inc. | Magnetically responsive nanoparticle therapeutic constructs and methods of making and using |
US7723311B2 (en) * | 2003-06-18 | 2010-05-25 | Nanobiomagnetics, Inc. | Delivery of bioactive substances to target cells |
DE602004021847D1 (en) | 2003-11-27 | 2009-08-13 | Develogen Ag | METHOD FOR THE PREVENTION AND TREATMENT OF DIABETES WITH NEURTURINE |
US20050222127A1 (en) * | 2004-03-30 | 2005-10-06 | Alcon, Inc. | Use of Rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance |
KR20070027621A (en) * | 2004-06-08 | 2007-03-09 | 알자 코포레이션 | Preparation of macromolecular conjugates by four-component condensation reaction |
EP1765459B1 (en) | 2004-06-15 | 2018-11-28 | Cochlear Limited | Automatic determination of the threshold of an evoked neural response |
TW200719884A (en) * | 2005-03-10 | 2007-06-01 | 3M Innovative Properties Co | Methods of treating ear infections |
US8309057B2 (en) * | 2005-06-10 | 2012-11-13 | The Invention Science Fund I, Llc | Methods for elevating neurotrophic agents |
WO2007030743A2 (en) | 2005-09-08 | 2007-03-15 | Massachusetts Eye & Ear Infirmary | Cochlear implants containing biological cells and uses thereof |
EP1872790A1 (en) | 2006-06-26 | 2008-01-02 | DeveloGen Aktiengesellschaft | New formulation for increasing bioavailability of neurturin |
CN104288775A (en) * | 2007-11-05 | 2015-01-21 | 伊沃泰克国际有限公司 | Novel neurturin conjugates for pharmaceutical use |
KR20190026056A (en) | 2008-04-21 | 2019-03-12 | 오토노미, 인코포레이티드 | Auris formulations for treating otic diseases and conditions |
AU2010313456A1 (en) * | 2009-10-30 | 2012-05-17 | Ntf Therapeutics, Inc. | Improved neurturin molecules |
US20110195439A1 (en) * | 2010-02-10 | 2011-08-11 | Selinfreund Richard H | Systems and methods for determining cardiac conditions |
WO2015191950A1 (en) * | 2014-06-12 | 2015-12-17 | Orbis Biosciences, Inc. | Extended-release drug delivery compositions |
TWI710635B (en) | 2014-10-09 | 2020-11-21 | 美商珍維克公司 | Adenoviral vector encoding human atonal homolog-1 (hath1) |
WO2020045980A1 (en) * | 2018-08-28 | 2020-03-05 | Industry-Academic Cooperation Foundation, Yonsei University | Pharmaceutical composition for treating or preventing sensorineural hearing loss |
CN110124014A (en) * | 2019-05-16 | 2019-08-16 | 杭州师范大学 | Recombinant human nerve enation factor Neuritin albumen application and it is a kind of for treating the drug of Auditory Neuropathy |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4518584A (en) * | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
US5106627A (en) * | 1987-11-17 | 1992-04-21 | Brown University Research Foundation | Neurological therapy devices |
JP2989002B2 (en) * | 1988-12-22 | 1999-12-13 | キリン―アムジエン・インコーポレーテツド | Chemically modified granulocyte colony stimulating factor |
WO1991010470A1 (en) * | 1990-01-08 | 1991-07-25 | Brown University Research Foundation | Devices and methods for enhanced delivery of active factors |
EP0610254B1 (en) * | 1991-09-20 | 2004-09-01 | Amgen Inc. | Glial derived neurotrophic factor |
ATE218893T1 (en) * | 1993-08-12 | 2002-06-15 | Neurotech Sa | BIOCOMPATIBLE IMMUNOISOLATION CAPSULES CONTAINING GENETICALLY MODIFIED CELLS |
FR2717824B1 (en) * | 1994-03-25 | 1996-04-26 | Rhone Poulenc Rorer Sa | Recombinant viruses, preparation and use in gene therapy. |
US5658785A (en) * | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
US5739307A (en) * | 1995-08-28 | 1998-04-14 | Washington University | Polynucleotide encoding neurturin neurotrophic factor |
AU1121997A (en) * | 1995-11-29 | 1997-06-19 | Amgen, Inc. | Method for treating sensory neuropathy using glial cell line-derived neurotrophic factor (gdnf) protein product |
US5929041A (en) * | 1996-02-23 | 1999-07-27 | Amgen Inc. | Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product |
US6043221A (en) * | 1997-07-30 | 2000-03-28 | Amgen Inc. | Method for preventing and treating hearing loss using a neuturin protein product |
-
1998
- 1998-06-29 US US09/106,486 patent/US6043221A/en not_active Expired - Lifetime
- 1998-07-17 DE DE69810635T patent/DE69810635T2/en not_active Expired - Fee Related
- 1998-07-17 ES ES98937956T patent/ES2190093T3/en not_active Expired - Lifetime
- 1998-07-17 AT AT98937956T patent/ATE230607T1/en not_active IP Right Cessation
- 1998-07-17 DK DK98937956T patent/DK1005358T3/en active
- 1998-07-17 EP EP98937956A patent/EP1005358B1/en not_active Expired - Lifetime
- 1998-07-17 AU AU86582/98A patent/AU8658298A/en not_active Abandoned
- 1998-07-17 WO PCT/US1998/014600 patent/WO1999006064A1/en active IP Right Grant
- 1998-07-17 JP JP2000504876A patent/JP2001525316A/en active Pending
- 1998-07-17 CA CA002298414A patent/CA2298414C/en not_active Expired - Fee Related
-
1999
- 1999-08-19 US US09/377,446 patent/US6274554B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2001525316A (en) | 2001-12-11 |
ATE230607T1 (en) | 2003-01-15 |
EP1005358B1 (en) | 2003-01-08 |
DE69810635T2 (en) | 2003-05-28 |
CA2298414C (en) | 2004-09-28 |
AU8658298A (en) | 1999-02-22 |
DK1005358T3 (en) | 2003-02-24 |
DE69810635D1 (en) | 2003-02-13 |
US6043221A (en) | 2000-03-28 |
US6274554B1 (en) | 2001-08-14 |
EP1005358A1 (en) | 2000-06-07 |
WO1999006064A1 (en) | 1999-02-11 |
ES2190093T3 (en) | 2003-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2298414A1 (en) | Method for preventing and treating hearing loss using a neurturin protein product | |
CA2217565A1 (en) | Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor (gdnf) protein product | |
AU1505788A (en) | A method and a composition for treating neurological diseases such as migraine, by influencing the nerve cells | |
AU6775196A (en) | Multi-electrode cochlear implant | |
CA2236158A1 (en) | Method for treating retinal ganglion cell injury using glial cell line-derived neurotrophic factor (gdnf) protein product | |
ITTO930721A0 (en) | IMPLANTABLE ELECTRODE, FOR EXAMPLE FOR PACEMAKERS, DEFIBRILLATORS AND SIMILAR. | |
AU4565096A (en) | An implantable atrial defibrillator having ischemia coordinated intervention therapy and method | |
CA2154424A1 (en) | 1-phenyl-3-dimethylaminopropane compounds having a pharmaceutical effect | |
CA2272584A1 (en) | Novel substituted pyrazole derivatives for the treatment of cardiocirculatory diseases | |
AU2455695A (en) | Amino acid amide derivative, process for producing the same,agrohorticultural fungicide, and fungicidal method | |
AU2746897A (en) | Techniques for treating epilepsy by brain stimulation and drug infusion | |
CA2186260A1 (en) | Composition comprising morphine, polypyrrolidone and a polyalkyleneoxide | |
HK1040053A1 (en) | Use of fused pyrrolocarbazoles for preventing/treating damage to sensory hair cells and cochlear neurons | |
IE791235L (en) | Acyl-derivatives of carnitine. | |
AU2825295A (en) | Method for the treatment, prevention or minimization of hair loss | |
CA2347863A1 (en) | Treatment of disorders of the outer retina | |
AU6241096A (en) | A cosmetic antimycotic composition for skin applications and pharmaceutical composition for the treatment of tumorous cells, bladder or nerve disorders | |
AU1867297A (en) | Gene-therapeutic nucleic acid construct, production of same and use of same in the treatment of heart disorders | |
EP1304119A3 (en) | Method for preventing and treating hearing loss using a neurturin protein product | |
AU1032699A (en) | Concentrate of natural antioxidant dietetic fiber from grape, and preparat ion process | |
CA2353527A1 (en) | Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases | |
AU5251999A (en) | Method of reducing retinal ganglion cell degeneration | |
AU692030B2 (en) | Hydantoin derivatives, process for producing the same and herbicides comprising the same as active ingredients | |
WO1994025012A3 (en) | Medicaments for treatment of migraine, epilepsy and feeding disorders | |
ZA969139B (en) | Pure 3R-3'R stereoisomer of zeaxanthin for treating macular degeneration in humans. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |